The importance of non-human primates for preclinical testing of immunosuppressive monoclonal antibodies.
Monoclonal antibodies (MAb) specific for lymphocyte markers can be considered as very specific immunomodulating drugs for treatment of allograft rejection and autoimmune diseases. Although the selection of potentially useful specificities of MAb can be made in rodents, human specific MAb can only be evaluated in man or a closely related species in which these human specific MAb are equally reactive. Because of the restricted reactivity of human specific MAb, non-human primates are the only available species for efficacy and safety studies. This article illustrates the usefulness of such studies in rhesus monkeys and chimpanzees for the testing of T cell specific MAb and other MAb interfering with the immune response in transplantation and autoimmunity.
Jonker
M
M
Institute for Applied Radiobiology and Immunology ITRI-TNO, Department of Chronic and Infectious Diseases, Rijswijk, Netherlands.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000633:toxicity; D000961:Antilymphocyte Serum / Q000494:pharmacology / Q000633:toxicity; D015551:Autoimmunity; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007165:Immunosuppression Therapy; D051379:Mice; D011323:Primates; D013045:Species Specificity; D014181:Transplantation Immunology
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum